ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Infection"

  • Abstract Number: 0632 • ACR Convergence 2020

    Systems Approach to Understanding Reasons for Influenza Vaccine Hesitancy in Rheumatic Diseases

    Valeria Valerio1, Mariana Useche1, Erin Field2, Mianbo Wang3, Elizabeth M. Hazel4, Brian Ward5 and Ines Colmegna1, 1The Research Institute of the McGill University Health Centre, Montreal, Canada, 2The Research Institute of the MUHC, Montreal, Canada, 3Lady Davis institute for Medical Research, Montreal, QC, Canada, 4McGill University Health Centre, Montreal, Canada, 5The Research Institute of the McGill University Health Centre, Monreal, QC, Canada

    Background/Purpose: A vaccination coverage goal of 80% with the seasonal influenza vaccine was established to protect people at high-risk for influenza-related complications or hospitalizations (e.g.…
  • Abstract Number: 1478 • ACR Convergence 2020

    A Multidisciplinary Registry of Patients with Autoinmune and Immune-Mediated Diseases with Symptomatic COVID-19 Infection from a Single Center

    Juan C Sarmiento-Monroy1, Gerard Espinosa2, Fernanda Meira1, Berta Caballol3, Maria C Londoño3, Sara Llufriu3, Aina Moll1, Luis Fernando Quintana Porras1, Felipe Julio Ramirez Garcia4, José Inciarte-Mundo1, Elisabeth Solana1, Yolanda Blanco1, Eugenia Martinez1, Victor Llorens1, Sergio Prieto-González5, Georgina Espigol1, Jose C Milisenda1, Maria C. Cid5, Priscila Giavedoni1, Jose M Mascaró1, Isabel Blanco1, Joan Albert Barbera1, Oriol Sibila1, Jordi Gratacos-Gines1, Alfredo Adan2, Alvaro Agustí1, Raimon Sanmartí6, Julián Panés1, Ricard Cervera1, Jordi Vila1, Alex Soriano1, Jose Gómez-Puerta6 and On behalf INMUNOCOVID CLINIC7, 1Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, 2Hospital Clinic, Barcelona, Catalonia, Spain, 3Hospital Clinic de Barcelona, Barcelona, Spain, 4Arthritis Unit, Rheumatology Dpt, Hospital Clinic, Barcelona, Spain, Barcelona, Catalonia, Spain, 5Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Barcelona, Catalonia, Spain, 6Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, 7Hospital Clinic de Barcelona, Barcelona

    Background/Purpose: National health authorities reported a prevalence of SARS-CoV-2 infection around 7% of the general population in Barcelona county (1). A recent report focused on…
  • Abstract Number: 0227 • ACR Convergence 2020

    Real Life Severe Infections in Patients with Rheumatoid Arthritis on Treatment with Biological Therapy and JAK Inhibitors

    Lucía Vega-Álvarez1, Itziar Calvo-Zorrilla1, Oihane Ibarguengoitia-Barrena1, Juan M. Blanco-Madrigal1, David Montero-Seisdedos2, Carmen L. Garcia-Gomez1, Maria Esther Ruiz-Lucea1, Ana R. Inchaurbe-Pellejero1, Ignacio Torre-Salaberri1, Clara E. Perez-Velasquez1, Olaia Fernandez-Berrizbeitia1, Eduardo Cuende-Quintana3, Iñigo R. Gorostiza-Hormaetxe4, María Luz García-Vivar1 and Eva Galindez-Agirregoikoa1, 1Basurto University Hospital, BILBAO, Spain, 2Basurto University Hospital, Bilbao, Pais Vasco, Spain, 3Basurto University Hospital, Madrid, Spain, 4Basurto University Hospital, Bilbao

    Background/Purpose: Infections are one of the main complications among patients with rheumatoid arthritis (RA) with immunosuppressive treatment. The differences between treatments and the influence of…
  • Abstract Number: 0633 • ACR Convergence 2020

    Vitamin D Serum Status in a Cohort of COVID-19 Patients

    Alberto Sulli1, Emanuele Gotelli1, Sabrina Paolino1, Andrea Casabella1, Carmen Pizzorni1, Elisa Alessandri1, Vanessa Smith2 and Maurizio Cutolo1, 1Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genoa, Italy, 2Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, VIB Inflammation Research Centre Ghent University, Ghent, Belgium

    Background/Purpose: Vitamin D serum levels have been inversely associated with risk of pulmonary infections and autoimmune inflammatory disease activity and severity [1,2]. A possible role…
  • Abstract Number: 1568 • ACR Convergence 2020

    Impact of the SARS-CoV-2 Pandemic on a Cohort of Patients with Rheumatic Complications of Immune Checkpoint Inhibitors: A Registry Survey Study

    Nilasha Ghosh1, Aidan Tirpack2, Caroline Benson3, Gregory Vitone3, Karmela Kim Chan2 and Anne Bass1, 1Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Hospital for Special Surgery, New York

    Background/Purpose: It is not known whether cancer patients being treated with immune checkpoint inhibitors (ICI) and/or immunosuppression are more vulnerable to SARS-CoV-2 or more apt…
  • Abstract Number: 008 • 2020 Pediatric Rheumatology Symposium

    Incidence and Risk Factors of Hypogammaglobulinemia and Infectious Complications Associated with Rituximab Use in Pediatric Rheumatic Diseases

    Mei-Sing Ong1, Deborah Rothman 2 and Marc Natter 3, 1Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, 2Massachusetts General Hospital, Springfield, 3Boston Children's Hospital, Boston

    Background/Purpose: B-cell depletion therapy has increasingly been used for the treatment of childhood-onset rheumatic diseases. Previous studies investigating whether rituximab results in increased infections have…
  • Abstract Number: 069 • 2020 Pediatric Rheumatology Symposium

    Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up

    Liora Harel 1, Gil Amarilyo 2 and mohammad hammad saied3, 1Schneider Hospital, Tel Aviv University, Petah-Tiqva, Israel, 2Schneider Hospital, Tel Aviv University, Kibbutz Magal, Israel, 3Schneider Medical Center, Kaboul village 24963, Israel

    Background/Purpose: Rheumatic Fever (RF) occurs after a pharyngeal infection caused by group A-B-hemolytic streptococci.Its principal clinical significance is causing carditis at the acute phase of…
  • Abstract Number: 138 • 2020 Pediatric Rheumatology Symposium

    Serious Infection Risk in Pediatric Patients with Low Immunoglobulin Levels Following Rituximab Treatment for Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

    Simone Melega 1, Paul Brogan2, Gavin Cleary 3, Aimee Hersh 4, Ozgur Kasapcopur 5, Satyapal Rangaraj 6, Rae Yeung 7, Andrew Zeft 8, Jennifer Cooper 9, Pooneh Pordeli 10, Petra Kirchner 11 and Patricia Lehane 12, 1F. Hoffmann-La Roche, Ltd., Basel, Switzerland, 2UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 3Alder Hey Children's Hospital, Liverpool, United Kingdom, 4University of Utah Primary Children's Hospital, Salt Lake City, 5Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Cerrahpasa, Turkey, 6Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, 7The Hospital for Sick Children, Toronto, Canada, 8The Cleveland Clinic - Center for Pediatric Rheumatology & Immunology, Cleveland, Ohio, 9University of Colorado, Children's Hospital Colorado, Denver, 10F. Hoffmann-La Roche, Ltd., Mississauga, Canada, 11F. Hoffmann-La Roche Ltd., Birsfelden, Switzerland, 12Roche Products Ltd., Welwyn Garden City, United Kingdom

    Background/Purpose: Low immunoglobulin (Ig) levels can occur after rituximab treatment, but the clinical significance is not completely understood. Not all patients (pts) who develop low…
  • Abstract Number: 2873 • 2019 ACR/ARP Annual Meeting

    Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further Increases with First-Line TNFi Therapy – Nationwide Results from Iceland

    Aron H Bjornsson1, Olafur Palsson 2, Mar Kristjansson 3, Petur S Gunnarsson 4, Gerdur Grondal 5, Bjorn Gudbjornsson 6 and Thorvardur J Love 7, 1Department of Medicine, Landspitali, Reykjavík, Iceland, 2Department of Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, Sweden, 3Department of Infectious Diseases, Landspitali, Reykjavík, Iceland, 4Faculty of Pharmaceutical Sciences, University of Iceland and Hospital Pharmacy, Landspitali, Reykjavík, Iceland, 5Department of Rheumatology, Landspitali and Centre for Rheumatology Research, Landspitali, Reykjavík, Iceland, 6Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 7Faculty of Medicine, University of Iceland and Department of Science, Landspitali, Reykjavík, Iceland

    Background/Purpose: Severe infections, frequently resulting in hospitalization, are a well-known adverse effects of tumor necrosis factor inhibitors (TNFi). However, studies regarding outpatient treated infections are…
  • Abstract Number: 848 • 2019 ACR/ARP Annual Meeting

    Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis

    Michael George1, Joshua Baker 2, Kevin Winthrop 3, Qufei Wu 2, Lang Chen 4, Fenglong Xie 5, Huifeng Yun 4 and Jeffrey Curtis 4, 1University of Pennsylvania, Philadelphia, 2University of Pennsylvania, Philadelphia, PA, 3Oregon Health and Science University, Portland, OR, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Alabama at Birmingham, Birmingham

    Background/Purpose: As many as 30-40% of patients with RA remain on long term glucocorticoids. Infection risk with higher dose glucocorticoids is well known, but evidence…
  • Abstract Number: 951 • 2019 ACR/ARP Annual Meeting

    Avoidable Acute Care Use for Vaccine-Preventable Illnesses Among Medicaid Beneficiaries with Lupus: Demographic and Healthcare Utilization Differences

    Candace Feldman1, Chang Xu 1 and Karen Costenbader 1, 1Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Nearly 25% of patients with SLE are hospitalized each year often for outcomes that may have been avoided if patients had received sustained, high…
  • Abstract Number: 1374 • 2019 ACR/ARP Annual Meeting

    Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US

    Robin Dore1, Jenya Antonova 2, Huan Huang 3, Lawrence Chang 2, Xin Wang 3 and Mark Genovese 4, 1Private practice, Tustin, CA, 2Gilead Sciences, Foster City, CA, 3IQVIA, Plymouth Meeting, PA, 4Stanford University, Stanford, CA

    Background/Purpose: Infections are common safety events monitored in RA patients.1 ACR guidelines limit the use of live vaccines in patients who are on biologic (b)DMARDs…
  • Abstract Number: 1515 • 2019 ACR/ARP Annual Meeting

    Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials

    Marina Magrey1, Victoria Navarro-Compán 2, Sandra Garces 3, Xenofon Baraliakos 4, David Sandoval 3, Jeffrey Lisse 3, Silvia Santisteban 3, David Adams 3, Fangyi Zhao 3 and Robert Inman 5, 1Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, 2University Hospital La Paz, IdiPaz, Madrid, Spain, 3Eli Lilly and Company, Indianapolis, IN, 4Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, 5University of Toronto, University Health Network, Toronto, ON, Canada

    Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A. IL-17 inhibitors have shown efficacy for radiographic axial spondyloarthritis (r-axSpA), with IXE currently…
  • Abstract Number: 1805 • 2019 ACR/ARP Annual Meeting

    Perioperative Anti-rheumatic Medications Are Not Associated with 30-day Odds of Infection in Rheumatoid Arthritis Patients Undergoing Surgery: A Retrospective Cohort Study

    Marianne Kerski1, Peter Boersma 2, Eric Miller 3, Ashley Brenner 4, Genevieve Melton 5 and Anna Shmagel 6, 1University of Minnesota Medical School, Minneapolis, MN, 2University of Minnesota School of Public Health, Minneapolis, 3University of Minnesota, Woodbury, MN, 4University of Minnesota Best Practices Integrated Informatics Core (BPIC), Minneapolis, MN, 5University of Minnesota Department of Surgery, Minneapolis, MN, 6University of Minnesota, Minneapolis, MN

    Background/Purpose: Perioperative management of anti-rheumatic drugs in rheumatoid arthritis (RA) patients undergoing surgery remains controversial. Previous studies produced conflicting results, and data on non-orthopedic surgeries…
  • Abstract Number: 2095 • 2019 ACR/ARP Annual Meeting

    A Quality Improvement Intervention to Improve Influenza and Pneumococcal Vaccination Rates in Immunosuppressed Inflammatory Arthritis Outpatients

    Kieran Murray1, Candice Low 1, Francis Young 1, Anna O'Rourke 1, Ian Callanan 2, Eoin Feeney 1 and Douglas Veale 3, 1Saint Vincent's University Hospital, Dublin, Ireland, 2Saint Vincent's University Hospital, Dublin, Dublin, Ireland, 3EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland

    Background/Purpose: The ACR and CDC recommend influenza (“flu”) and 23-valent pneumococcal polysaccharide (PPSV23) vaccination for inflammatory arthritis (IA) patients on immunosuppression. This study aimed to:…
  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 36
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology